Perspectives on urea cycle disorder management: Results of a clinician survey.

Abstract

BACKGROUND/AIMS:

Urea cycle disorders (UCDs) are rare inborn errors of urea synthesis. US and European consensus statements on the diagnosis and treatment of UCDs were last published in 2001 and 2019, respectively. Recommendations are based primarily on case reports and expert opinion and there is limited agreement or consistency related to long-term management approaches. A clinician survey was conducted to assess current real-world practices and perspectives on challenges and unmet needs.

METHODS:

A 14-item multiple-choice survey was administered to physicians in 2017. Clinicians who reported actively managing at least 1 patient with UCD were eligible to participate. Descriptive statistics were calculated for each survey item (frequencies for categorical variables; means, standard deviations, medians, and ranges for continuous variables).

RESULTS:

Sixty-six US clinicians completed the survey (65 geneticists; 1 pediatric neurologist). Over 90% of responders agreed or strongly agreed that even modest elevations in ammonia could cause physiological and functional brain damage; >80% of respondents agreed that asymptomatic UCD patients are at risk of brain damage over time due to mild/subclinical elevations in ammonia. Eighty-six percent of clinicians agreed or strongly agreed with recommending genetic testing for female relatives when a patient is diagnosed with ornithine transcarbamylase deficiency. Ninety-four percent of respondents agreed that patients have better disease control when they are more adherent to their UCD therapy. Nearly 90% indicated that clinicians and patients would benefit from updated UCD management guidance. More than half (53%) of respondents rated the symptoms of UCDs as extremely or very burdensome to the everyday lives of patients and their families; only 8% rated UCD symptoms as slightly or not at all burdensome. The majority of clinicians agreed (48%) or strongly agreed (32%) that caring for a child or family member with a UCD has a negative impact on the quality of life and/or health of family members/guardians (e.g. stress, relationships, ability to work).

CONCLUSIONS:

This self-reported survey suggests a need for updated and expanded clinical guidance on the long-term treatment and management of UCD patients.

• Authors: Gregory M Enns, Marty H Porter, Megan Francis-Sedlak, Andrea Burdett, Jerry Vockley
• Journal: Molecular genetics and metabolism (Mol Genet Metab) 2019 Sep - Oct Vol. 128 Issue 1-2 Pg. 102-108 ISSN: 1096-7206 [Electronic] United States
• PMID: 31377149 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Urea

Topics

• Disease Management
• Humans
• Hyperammonemia (diagnosis)
• Longitudinal Studies
• Physicians
• Quality of Life
• Surveys and Questionnaires
• Urea (metabolism)
• Urea Cycle Disorders, Inborn (diagnosis, drug therapy)